Cargando…

Stratifying Brain Tumour Histological Sub-Types: The Application of ATR-FTIR Serum Spectroscopy in Secondary Care

Patients living with brain tumours have the highest average years of life lost of any cancer, ultimately reducing average life expectancy by 20 years. Diagnosis depends on brain imaging and most often confirmatory tissue biopsy for histology. The majority of patients experience non-specific symptoms...

Descripción completa

Detalles Bibliográficos
Autores principales: Cameron, James M., Rinaldi, Christopher, Butler, Holly J., Hegarty, Mark G, Brennan, Paul M., Jenkinson, Michael D., Syed, Khaja, Ashton, Katherine M., Dawson, Timothy P., Palmer, David S., Baker, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408619/
https://www.ncbi.nlm.nih.gov/pubmed/32605100
http://dx.doi.org/10.3390/cancers12071710
_version_ 1783567872995360768
author Cameron, James M.
Rinaldi, Christopher
Butler, Holly J.
Hegarty, Mark G
Brennan, Paul M.
Jenkinson, Michael D.
Syed, Khaja
Ashton, Katherine M.
Dawson, Timothy P.
Palmer, David S.
Baker, Matthew J.
author_facet Cameron, James M.
Rinaldi, Christopher
Butler, Holly J.
Hegarty, Mark G
Brennan, Paul M.
Jenkinson, Michael D.
Syed, Khaja
Ashton, Katherine M.
Dawson, Timothy P.
Palmer, David S.
Baker, Matthew J.
author_sort Cameron, James M.
collection PubMed
description Patients living with brain tumours have the highest average years of life lost of any cancer, ultimately reducing average life expectancy by 20 years. Diagnosis depends on brain imaging and most often confirmatory tissue biopsy for histology. The majority of patients experience non-specific symptoms, such as headache, and may be reviewed in primary care on multiple occasions before diagnosis is made. Sixty-two per cent of patients are diagnosed on brain imaging performed when they deteriorate and present to the emergency department. Histological diagnosis from invasive surgical biopsy is necessary prior to definitive treatment, because imaging techniques alone have difficulty in distinguishing between several types of brain cancer. However, surgery itself does not necessarily control tumour growth, and risks morbidity for the patient. Due to their similar features on brain scans, glioblastoma, primary central nervous system lymphoma and brain metastases have been known to cause radiological confusion. Non-invasive tests that support stratification of tumour subtype would enhance early personalisation of treatment selection and reduce the delay and risks associated with surgery for many patients. Techniques involving vibrational spectroscopy, such as attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy, have previously demonstrated analytical capabilities for cancer diagnostics. In this study, infrared spectra from 641 blood serum samples obtained from brain cancer and control patients have been collected. Firstly, we highlight the capability of ATR-FTIR to distinguish between healthy controls and brain cancer at sensitivities and specificities above 90%, before defining subtle differences in protein secondary structures between patient groups through Amide I deconvolution. We successfully differentiate several types of brain lesions (glioblastoma, meningioma, primary central nervous system lymphoma and metastasis) with balanced accuracies >80%. A reliable blood serum test capable of stratifying brain tumours in secondary care could potentially avoid surgery and speed up the time to definitive therapy, which would be of great value for both neurologists and patients.
format Online
Article
Text
id pubmed-7408619
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74086192020-08-13 Stratifying Brain Tumour Histological Sub-Types: The Application of ATR-FTIR Serum Spectroscopy in Secondary Care Cameron, James M. Rinaldi, Christopher Butler, Holly J. Hegarty, Mark G Brennan, Paul M. Jenkinson, Michael D. Syed, Khaja Ashton, Katherine M. Dawson, Timothy P. Palmer, David S. Baker, Matthew J. Cancers (Basel) Article Patients living with brain tumours have the highest average years of life lost of any cancer, ultimately reducing average life expectancy by 20 years. Diagnosis depends on brain imaging and most often confirmatory tissue biopsy for histology. The majority of patients experience non-specific symptoms, such as headache, and may be reviewed in primary care on multiple occasions before diagnosis is made. Sixty-two per cent of patients are diagnosed on brain imaging performed when they deteriorate and present to the emergency department. Histological diagnosis from invasive surgical biopsy is necessary prior to definitive treatment, because imaging techniques alone have difficulty in distinguishing between several types of brain cancer. However, surgery itself does not necessarily control tumour growth, and risks morbidity for the patient. Due to their similar features on brain scans, glioblastoma, primary central nervous system lymphoma and brain metastases have been known to cause radiological confusion. Non-invasive tests that support stratification of tumour subtype would enhance early personalisation of treatment selection and reduce the delay and risks associated with surgery for many patients. Techniques involving vibrational spectroscopy, such as attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy, have previously demonstrated analytical capabilities for cancer diagnostics. In this study, infrared spectra from 641 blood serum samples obtained from brain cancer and control patients have been collected. Firstly, we highlight the capability of ATR-FTIR to distinguish between healthy controls and brain cancer at sensitivities and specificities above 90%, before defining subtle differences in protein secondary structures between patient groups through Amide I deconvolution. We successfully differentiate several types of brain lesions (glioblastoma, meningioma, primary central nervous system lymphoma and metastasis) with balanced accuracies >80%. A reliable blood serum test capable of stratifying brain tumours in secondary care could potentially avoid surgery and speed up the time to definitive therapy, which would be of great value for both neurologists and patients. MDPI 2020-06-27 /pmc/articles/PMC7408619/ /pubmed/32605100 http://dx.doi.org/10.3390/cancers12071710 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cameron, James M.
Rinaldi, Christopher
Butler, Holly J.
Hegarty, Mark G
Brennan, Paul M.
Jenkinson, Michael D.
Syed, Khaja
Ashton, Katherine M.
Dawson, Timothy P.
Palmer, David S.
Baker, Matthew J.
Stratifying Brain Tumour Histological Sub-Types: The Application of ATR-FTIR Serum Spectroscopy in Secondary Care
title Stratifying Brain Tumour Histological Sub-Types: The Application of ATR-FTIR Serum Spectroscopy in Secondary Care
title_full Stratifying Brain Tumour Histological Sub-Types: The Application of ATR-FTIR Serum Spectroscopy in Secondary Care
title_fullStr Stratifying Brain Tumour Histological Sub-Types: The Application of ATR-FTIR Serum Spectroscopy in Secondary Care
title_full_unstemmed Stratifying Brain Tumour Histological Sub-Types: The Application of ATR-FTIR Serum Spectroscopy in Secondary Care
title_short Stratifying Brain Tumour Histological Sub-Types: The Application of ATR-FTIR Serum Spectroscopy in Secondary Care
title_sort stratifying brain tumour histological sub-types: the application of atr-ftir serum spectroscopy in secondary care
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408619/
https://www.ncbi.nlm.nih.gov/pubmed/32605100
http://dx.doi.org/10.3390/cancers12071710
work_keys_str_mv AT cameronjamesm stratifyingbraintumourhistologicalsubtypestheapplicationofatrftirserumspectroscopyinsecondarycare
AT rinaldichristopher stratifyingbraintumourhistologicalsubtypestheapplicationofatrftirserumspectroscopyinsecondarycare
AT butlerhollyj stratifyingbraintumourhistologicalsubtypestheapplicationofatrftirserumspectroscopyinsecondarycare
AT hegartymarkg stratifyingbraintumourhistologicalsubtypestheapplicationofatrftirserumspectroscopyinsecondarycare
AT brennanpaulm stratifyingbraintumourhistologicalsubtypestheapplicationofatrftirserumspectroscopyinsecondarycare
AT jenkinsonmichaeld stratifyingbraintumourhistologicalsubtypestheapplicationofatrftirserumspectroscopyinsecondarycare
AT syedkhaja stratifyingbraintumourhistologicalsubtypestheapplicationofatrftirserumspectroscopyinsecondarycare
AT ashtonkatherinem stratifyingbraintumourhistologicalsubtypestheapplicationofatrftirserumspectroscopyinsecondarycare
AT dawsontimothyp stratifyingbraintumourhistologicalsubtypestheapplicationofatrftirserumspectroscopyinsecondarycare
AT palmerdavids stratifyingbraintumourhistologicalsubtypestheapplicationofatrftirserumspectroscopyinsecondarycare
AT bakermatthewj stratifyingbraintumourhistologicalsubtypestheapplicationofatrftirserumspectroscopyinsecondarycare